MyChesCo on MSN26 分钟
Madrigal Pharmaceuticals Reports Promising Two-Year Results for MASH Therapy
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced positive two-year results from the Phase 3 MAESTRO-NAFLD-1 trial, ...